Psychiatrist kills ads to pay ransom

A leading child psychiatrist got thousands of emails this week criticizing a provocative advertising campaign by his center to raise awareness of mental illness in children. The New York Times linkurl:reported;http://www.nytimes.com/2007/12/20/business/media/20child.html that Harold Koplewicz, the director of New York University's Child Study Center, received more than 3,000 emails in response to the ads, which used fake ransom notes to call attention to autism and depression in children. For e

Written byIvan Oransky
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
A leading child psychiatrist got thousands of emails this week criticizing a provocative advertising campaign by his center to raise awareness of mental illness in children. The New York Times linkurl:reported;http://www.nytimes.com/2007/12/20/business/media/20child.html that Harold Koplewicz, the director of New York University's Child Study Center, received more than 3,000 emails in response to the ads, which used fake ransom notes to call attention to autism and depression in children. For example: ''We have your son. We will make sure he will no longer be able to care for himself or interact socially as long as he lives.'' Koplewicz told the Times that 70% of those emails were negative, and in response, the Center has decided to end the campaign. Koplewicz's name may be familiar to readers of The Scientist. He was the co-author of a linkurl:piece on childhood psychosis;http://www.the-scientist.com/supplement/2007-12-1/ in our recently published linkurl:supplement;http://www.the-scientist.com/2007/12/01/s22/1/ on schizophrenia. The point of that supplement was to raise awareness of schizophrenia in the research community, and help set the agenda for research into the devastating condition. Koplewicz was no doubt hoping to do the same with the ads.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies